These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1320587)

  • 1. OHIO-1 beta-lactamase resistant to mechanism-based inactivators.
    Bonomo RA; Currie-McCumber C; Shlaes DM
    FEMS Microbiol Lett; 1992 Apr; 71(1):79-82. PubMed ID: 1320587
    [No Abstract]   [Full Text] [Related]  

  • 2. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
    Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
    Moosdeen F; Keeble J; Williams JD
    Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
    Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
    Reguera JA; Baquero F; Pérez-Díaz JC; Martínez JL
    J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
    London N; Thomson CJ; Amyes SG; Stobberingh E
    FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity of a sulphone beta-lactamase inhibitor, YTR 830.
    Moosdeen F; Williams J; Yamabe S
    Chemioterapia; 1987 Jun; 6(2 Suppl):206-7. PubMed ID: 2855613
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
    Lachance N; Gaudreau C; Lamothe F; Turgeon F
    Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
    Corkill JE; Hart CA; McLennan AG; Aspinall S
    J Gen Microbiol; 1991 Jun; 137(6):1425-9. PubMed ID: 1655952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of beta-lactamase inhibitors with various beta-lactamases.
    Cullmann W
    Chemotherapy; 1990; 36(3):200-8. PubMed ID: 2159863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate.
    Shen Z; Ding B; Bi Y; Wu S; Xu S; Xu X; Guo Q; Wang M
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    J Antimicrob Chemother; 1992 Jul; 30(1):17-25. PubMed ID: 1331018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.
    Chaibi EB; Péduzzi J; Farzaneh S; Barthélémy M; Sirot D; Labia R
    Biochim Biophys Acta; 1998 Jan; 1382(1):38-46. PubMed ID: 9507060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.